The Novo Nordisk Foundation committed up to DKK 5.5 billion (about $850–$857 million) to Denmark’s BioInnovation Institute to scale early‑stage life‑science commercialization across Europe. The multi‑year funding framework will expand BII’s capacity, double annual startup support from 20 to 40 companies, and extend the institute’s geographic reach beyond Denmark. Foundation and BII officials said the capital will underwrite translation infrastructure, commercialization programs, and partnerships to attract investors and industry collaborators. The move signals a strategic push to close Europe’s gap in converting world‑class research into companies and jobs. Industry observers note the pledge could accelerate spinouts, strengthen Europe’s translational pipeline, and increase availability of pre‑seed funding — but success will hinge on follow‑on private capital and measurable exits.